Effect of low-dose valsartan on proteinuria in normotensive immunoglobulin A nephropathy with minimal proteinuria: a randomized trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jo, Young-Il | - |
dc.contributor.author | Na, Ha-Young | - |
dc.contributor.author | Moon, Ju-Young | - |
dc.contributor.author | Han, Sang-Woong | - |
dc.contributor.author | Yang, Dong-Ho | - |
dc.contributor.author | Lee, Sang-Ho | - |
dc.contributor.author | Park, Hyeong-Cheon | - |
dc.contributor.author | Choi, Hoon-Young | - |
dc.contributor.author | Lim, So-Dug | - |
dc.contributor.author | Kie, Jeong-Hae | - |
dc.contributor.author | Lee, Yong-Kyu | - |
dc.contributor.author | Shin, Sug-Kyun | - |
dc.date.accessioned | 2021-07-30T05:30:04Z | - |
dc.date.available | 2021-07-30T05:30:04Z | - |
dc.date.created | 2021-05-11 | - |
dc.date.issued | 2016-03 | - |
dc.identifier.issn | 1226-3303 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/5117 | - |
dc.description.abstract | Background/Aims: Immunoglobulin A nephropathy (IgAN) is a generally progressive disease, even in patients with favorable prognostic features. In this study, we aimed to investigate the antiproteinuric effect and tolerability of low-dose valsartan (an angiotensin II receptor blocker) therapy in normotensive IgAN patients with minimal proteinuria of less than 0.5 to 1.0 g/day. Methods: Normotensive IgAN patients, who had persistent proteinuria with a spot urine protein-to-creatinine ratio of 0.3 to 1.0 mg/mg creatinine, were recruited from five hospitals and randomly assigned to either 40 mg of valsartan as the low-dose group or 80 mg of valsartan as the regular-dose group. Clinical and laboratory data were collected at baseline, and at 4, 8, 12, and 24 weeks after valsartan therapy. Results: Forty-three patients (low-dose group, n = 23; regular-dose group, n = 20) were enrolled in the study. Proteinuria decreased significantly not only in the regular-dose group but also in the low-dose group. The change in urine protein-to-creatinine ratio at week 24 was −41.3% ± 26.1% (p < 0.001) in the regular-dose group and −21.1% ± 45.1% (p = 0.005) in the low-dose group. In the low-dose group, blood pressure was constant throughout the study period, and there was no symptomatic hypotension. In the regular-dose group, blood pressure decreased at weeks 8 and 12. No significant change in glomerular filtration rate, serum creatinine level, or serum potassium level was observed during the study period. Conclusions: Our results suggest that low-dose valsartan can significantly reduce proteinuria without causing any intolerability in normotensive IgAN patients with minimal proteinuria. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | KOREAN ASSOC INTERNAL MEDICINE | - |
dc.title | Effect of low-dose valsartan on proteinuria in normotensive immunoglobulin A nephropathy with minimal proteinuria: a randomized trial | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Han, Sang-Woong | - |
dc.identifier.doi | 10.3904/kjim.2014.266 | - |
dc.identifier.scopusid | 2-s2.0-84960075383 | - |
dc.identifier.wosid | 000372174600015 | - |
dc.identifier.bibliographicCitation | KOREAN JOURNAL OF INTERNAL MEDICINE, v.31, no.2, pp.335 - 343 | - |
dc.relation.isPartOf | KOREAN JOURNAL OF INTERNAL MEDICINE | - |
dc.citation.title | KOREAN JOURNAL OF INTERNAL MEDICINE | - |
dc.citation.volume | 31 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 335 | - |
dc.citation.endPage | 343 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002089201 | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | IGA NEPHROPATHY | - |
dc.subject.keywordPlus | REDUCES PROTEINURIA | - |
dc.subject.keywordPlus | MILD PROTEINURIA | - |
dc.subject.keywordPlus | NATURAL-HISTORY | - |
dc.subject.keywordPlus | LOSARTAN | - |
dc.subject.keywordPlus | REMISSION | - |
dc.subject.keywordPlus | DISEASE | - |
dc.subject.keywordPlus | PROGRESSION | - |
dc.subject.keywordPlus | INHIBITORS | - |
dc.subject.keywordPlus | PROGNOSIS | - |
dc.subject.keywordAuthor | Angiotensin receptor antagonists | - |
dc.subject.keywordAuthor | Glomerulonephritis | - |
dc.subject.keywordAuthor | IGA | - |
dc.subject.keywordAuthor | Proteinuria | - |
dc.subject.keywordAuthor | Safety | - |
dc.subject.keywordAuthor | Treatment outcome | - |
dc.identifier.url | https://www.kjim.org/journal/view.php?doi=10.3904/kjim.2014.266 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.